New study reveals how cancer drug affects other medications

NCT ID NCT07486713

First seen Mar 24, 2026 · Last updated May 16, 2026 · Updated 9 times

Summary

This study looks at how olutasidenib, a drug for certain cancers with an IDH1 mutation, changes the way the body processes other medications. Researchers will give participants a mix of test drugs before and during olutasidenib treatment to measure differences in drug levels. The goal is to understand potential interactions, helping doctors prescribe safer combinations. The study involves 16 adults with cancers like AML, glioma, or cholangiocarcinoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • New York Presbyterian Hospital-Columbia University Medical Center

    NOT_YET_RECRUITING

    New York, New York, 10032, United States

  • UCI Irvine Health

    RECRUITING

    Orange, California, 92868, United States

Conditions

Explore the condition pages connected to this study.